The Challenge
More than 500 million people worldwide live with osteoarthritis, making it one of the leading causes of chronic pain and disability globally. For many, everyday activities become increasingly difficult as pain, stiffness and reduced mobility take hold, affecting independence, wellbeing and quality of life.
Osteoarthritis has traditionally been seen as a simple “wear and tear” condition, but researchers now know the disease is far more complex, involving inflammation, immune system activity and biological changes within the joint itself. Despite its widespread impact, treatment options remain limited, and many people ultimately require joint replacement surgery. Understanding what drives the disease is critical to developing earlier and more effective treatments.
The role of philanthropy
Hearts & Minds funding, as nominated by Magellan Investment Partners, has helped provide a grant to St Vincent's Clinic Research Foundation (SVCRF) to establish the foundations for this research.This support has enabled researchers to build a specialised osteoarthritis biobank, collecting both biological samples and detailed patient information to better understand the disease.
During 2025, the team significantly expanded the St Vincent's–Garvan Osteoarthritis Tissue Biobank, collecting samples and clinical data from 105 patients undergoing joint replacement surgery. Researchers also generated advanced molecular datasets from 45 patients, more than doubling their original research target.
This support has helped transform the project from an emerging collaboration into an integrated precision medicine research platform connecting SVCRF, St Vincent's Private Hospital Sydney and the Garvan Institute.
What this could unlock
One of the most significant findings from this research is that patients with similar levels of joint damage can experience vastly different levels of pain and stiffness. This reinforces that osteoarthritis is not simply a mechanical condition, but a biologically complex disease that affects each person differently.
By linking patient symptoms with biological changes occurring inside affected joints, researchers are beginning to uncover the mechanisms driving disease progression. Early findings suggest immune cells may play a much larger role than previously understood, opening new avenues for treatment.
Over time, this work could help clinicians identify osteoarthritis earlier, better predict how the disease will progress, and tailor treatments to individual patients. By enabling intervention before irreversible joint damage occurs, the research has the potential to improve quality of life and reduce the need for joint replacement surgery.
For more insights, watch the panel discussion featuring A/Prof Sean Mungovan from St Vincent's Private Hospital Sydney and Dr Etienne Masle-Farquhar from the Garvan Institute.
This project is supported by Hearts and Minds Investments, as nominated by Core Fund Manager, Magellan Investment Partners. For further information and updates, visit SVCRF.
